Table 3.
—[Section 2.1] Summary of Findings: Parenteral Anticoagulation vs No Parenteral Anticoagulation in Acute VTEa,51
| Outcomes | No. of Participants (Studies), Follow-up | Quality of the Evidence (GRADE) | Relative Effect (95% CI) | Anticipated absolute
effects |
|
| Risk With No Parenteral Anticoagulation | Risk Difference With Parenteral Anticoagulation (95% CI) | ||||
| Mortality |
120 (1 study), 6 mo |
Moderateb,c due to imprecision |
RR 0.5 (0.05-5.37) |
33 per 1,000 |
16 fewer per 1,000 (from 31 fewer to 144 more) |
| VTE symptomatic extension or recurrence |
120 (1 study), 6 mo |
Moderateb,d due to imprecision |
RR 0.33 (0.11-0.98) |
200 per 1,000 |
134 fewer per 1,000 (from 4 fewer to 178 fewer) |
| Major bleeding | 120 (1 study), 6 mo | Moderateb,c due to imprecision | RR 0.67 (0.12-3.85) | 50 per 1,000 | 16 fewer per 1,000 (from 44 fewer to 142 more) |
The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Working group grades of evidence are as follow: High quality, further research is very unlikely to change our confidence in the estimate of effect; moderate quality, further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality, further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very-low quality, we are very uncertain about the estimate. GRADE = Grades of Recommendations, Assessment, Development, and Evaluation; RR = risk ratio.
Both groups treated with acenocoumarol
Study described as double blinded; outcome adjudicators blinded. None of the study participants were lost to follow-up. Intention-to-treat analysis. Study was stopped early for benefit.
CI includes values suggesting no effect as well as values suggesting either appreciable benefit or appreciable harm.
Low number of events caused by the early stoppage of the trial.